Breaking News Instant updates and real-time market news.

THO

Thor Industries

$90.44

-0.23 (-0.25%)

, VNET

21Vianet

$7.62

-0.09 (-1.17%)

17:36
11/28/16
11/28
17:36
11/28/16
17:36

On The Fly: After Hours Movers

UP AFTER EARNINGS: Thor Industries (THO), up 8.6%... 21Vianet (VNET), up 4.7%... ZTO Express (ZTO), up 2.5%. ALSO HIGHER: TiVo (TIVO), up 4.8% after it signed licensing agreements with Netflix (NFLX)... UnitedHealth (UNH), up 2% after it backed its fiscal 2016 guidance and provided guidance for fiscal 2017. DOWN AFTER EARNINGS: Shoe Carnival (SCVL), down 10.9%. ALSO LOWER: Nivalis (NVLS), down 52.5% after it said that its Phase 2 cavosontat trial did not meet its primary endpoint... Amicus (FOLD), down 26.8% after ruling out accelerated approval for its migalastat product and confirming the need for additional data... Cotiviti Holdings (COTV), down 4.3% after it filed to sell 10M shares of common stock... Bojangles (BOJA), down 4.1% after it filed to sell 6M shares of common stock for holders... Texas Capital (TCBI), down 3.6% after it filed to sell 3M shares of common stock... SiteOne Landscape (SITE), down 3% after it filed to sell 8M shares of common stock for holders... Cherokee (CHKE), down 2.5% after it filed to sell common stock and announced its intent to acquire Hi-Tec Sports... Allstate (ALL), down 1.4% after it agreed to acquire SquareTrade for roughly $1.4B.

THO

Thor Industries

$90.44

-0.23 (-0.25%)

VNET

21Vianet

$7.62

-0.09 (-1.17%)

ZTO

ZTO Express

$15.81

-0.09 (-0.57%)

TIVO

TiVo

$20.75

0.05 (0.24%)

NFLX

Netflix

$116.93

-0.48 (-0.41%)

UNH

UnitedHealth

$152.11

-0.7 (-0.46%)

SCVL

Shoe Carnival

$30.27

-1.18 (-3.75%)

NVLS

Nivalis Therapeutics

$6.25

-0.03 (-0.48%)

FOLD

Amicus

$8.32

-0.58 (-6.52%)

COTV

Cotiviti Holdings

$31.45

-0.43 (-1.35%)

BOJA

Bojangles

$19.70

-0.35 (-1.75%)

TCBI

Texas Capital

$73.15

-2.35 (-3.11%)

SITE

SiteOne Landscape

$35.07

-0.53 (-1.49%)

CHKE

Cherokee

$10.00

-0.5 (-4.76%)

ALL

Allstate

$72.04

-0.01 (-0.01%)

  • 28

    Nov

  • 28

    Nov

  • 29

    Nov

  • 29

    Nov

  • 29

    Nov

  • 30

    Nov

  • 01

    Dec

  • 05

    Dec

  • 09

    Jan

  • 29

    Nov

  • 29

    Nov

  • 30

    Nov

  • 01

    Dec

  • 01

    Dec

THO Thor Industries
$90.44

-0.23 (-0.25%)

09/28/16
WLSD
09/28/16
UPGRADE
WLSD
Buy
Thor Industries upgraded to Buy from Gradually Accumulate at Wellington Shields
09/13/16
NRCS
09/13/16
UPGRADE
Target $95
NRCS
Buy
Thor Industries upgraded to Buy from Neutral at Northcoast
Northcoast analyst Seth Woolf upgraded Thor Industries to Buy with a $95 price target. The analyst said the recent move in shares still doesn't reflect full accretion of the Jayco acquisition nor the strategic benefits. Woolf believes that the Jayco deal gives the company the best product portfolio in the industry. This is particularly true as it relates to Thor's ability to ride the wave of younger consumers entering the channel via entry-level travel trailers, the analyst wrote.
08/19/16
WDLK
08/19/16
DOWNGRADE
Target $80
WDLK
Hold
Thor Industries downgraded to Hold from Buy at Wunderlich
Wunderlich analyst Rommel Dionisio downgraded Thor Industries to Hold citing the recent rally in the shares. The analyst keeps an $80 price target for the name.
07/29/16
RHCO
07/29/16
UPGRADE
RHCO
Buy
Thor Industries upgraded on multiple catalysts at SunTrust
As noted earlier, SunTrust upgraded Thor to Buy from Neutral. Analyst Michael Swartz predicts that the company will benefit from higher than expected accretion and synergies from its Jayco acquisition, as well as 20%-40% growth in industry volumes by 2020. Target $90.
VNET 21Vianet
$7.62

-0.09 (-1.17%)

07/08/16
MSCO
07/08/16
DOWNGRADE
MSCO
Underweight
21Vianet downgraded to Underweight from Overweight at Morgan Stanley
Morgan Stanley assumed coverage on 21Vianet with an Underweight rating from an Overweight rating.
08/17/16
JPMS
08/17/16
DOWNGRADE
Target $5.6
JPMS
Underweight
21Vianet downgraded to Underweight from Neutral at JPMorgan
JPMorgan analyst Michelle Wei downgraded 21Vianet to Underweight following the company's Q2 results. The analyst lowered her price target for the shares to $5.60 from $21.
ZTO ZTO Express
$15.81

-0.09 (-0.57%)

11/23/16
11/23/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Philips (PHG) initiated with a Buy at Citi. 2. Rockwell Collins (COL) initiated with an Outperform at Wolfe Research. 3. Golar LNG (GLNG) assumed with a Buy at Seaport Global. 4. Cincinnati Bell (CBB) initiated with a Buy at Drexel Hamilton. 5. ZTO Express (ZTO) initiated with an Overweight at JPMorgan. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
11/21/16
MSCO
11/21/16
INITIATION
MSCO
Overweight
ZTO Express initiated with an Overweight at Morgan Stanley
Morgan Stanley analyst Edward Xu initiated ZTO Express with an Overweight and a $20 price target.
11/21/16
11/21/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Netflix (NFLX) initiated with a Buy at Brean Capital. 2. Allergan (AGN) initiated with a Market Perform at William Blair. 3. Myovant Sciences (MYOV) was initiated with an Overweight at Barclays, an Outperform at JMP Securities, an Outperform at Baird, a Buy at Citi, and an Outperform at Cowen. 4. RA Pharmaceuticals (RARX) was initiated with a Buy at Jefferies, a Buy at SunTrust, and an Outperform at Credit Suisse. 5. ZTO Express (ZTO) was initiated with a Buy ratings at Citi and Goldman and an Overweight at Morgan Stanley. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
11/23/16
JPMS
11/23/16
INITIATION
Target $19
JPMS
Overweight
ZTO Express initiated with an Overweight at JPMorgan
JPMorgan analyst Alex Yao started ZTO Express with an Overweight rating and $19 price target. Industry parcel volume growth is expected to remain strong, Yao tells investors in a research note.
TIVO TiVo
$20.75

0.05 (0.24%)

05/12/16
PIPR
05/12/16
NO CHANGE
Target $29
PIPR
Overweight
Rovi 8% pullback a buying opportunity, says Piper Jaffray
Piper Jaffray analyst Michael Olson views the 8% pullback in shares of Rovi (ROVI) over the past two weeks as a buying opportunity. Concerns around patent license renewals with three of the top-10 domestic service providers and trading around the acquisition of TiVo (ITVO) have pushed the stock lower, Olson tells investors in a research note. While a renewal with Comcast (CMCSA) does not appear imminent, DISH (DISH) and/or a third unnamed service provider could be signed within months, the analyst writes. He keeps an Overweight rating on Rovi with a $29 price target.
06/01/16
MKMP
06/01/16
DOWNGRADE
MKMP
Neutral
TiVo downgraded to Neutral from Buy at MKM Partners
10/31/16
JPMS
10/31/16
NO CHANGE
JPMS
Overweight
TiVo deal renewal shows IP portfolio strong, says JPMorgan
JPMorgan analyst Sterling Auty believes the worldwide multi-year renewal license with Panasonic (PCRFY) is another sign that TiVo's intellectual property portfolio remains strong. TiVo is positioned to land the last remaining pay TV operator out of contract in the U.S., Comcast (CMCSA), Auty tells investors in a research note. He keeps an Overweighrt rating on TiVo.
05/13/16
RILY
05/13/16
NO CHANGE
Target $29
RILY
Buy
Rovi added to Focus List at B. Riley
B. Riley analyst Eric Wold added Rovi (ROVI) to his firm's Focus List saying a near-term resolution with DISH/EchoStar should "provide a boost" to 2016 guidance. This catalyst combined with the accretive acquisition of TiVo could drive shares meaningfully higher in the coming months, Wold tells investors in a research note. He has a Buy rating on Rovi with a $29 price target.
NFLX Netflix
$116.93

-0.48 (-0.41%)

11/23/16
OPCO
11/23/16
NO CHANGE
OPCO
Facebook, Amazon.com most attractive on post-election pullback, says Oppenheimer
Oppenheimer analyst Jason Helfstein notes that there has been a rotation into industrial and financial stocks post-election, at the expense of multinational technology stocks. However, he sees some potential positive catalysts for "FANG" names, namely Facebook (FB), Amazon.com (AMZN), Netflix (NFLX) and Google (GOOG; GOOGL), with the first two looking the most attractive at current levels. The analyst points out that Facebook's potential positive catalysts include faster than expected ad monetization driven by "Video First" strategy, Instagram engagement and Dynamic Product Ads. As for Amazon, he expects stable consumer spending to support a strong holiday shopping season.
11/21/16
BMUR
11/21/16
INITIATION
Target $145
BMUR
Buy
Netflix initiated with a Buy at Brean Capital
Brean Capital analyst Alan Gould started Netflix with a Buy rating and $145 price target. The company has created an "unstoppable lead" in the internet TV business and is positioned to dominate the business long term, Gould tells investors in a research note. He believes Netflix over the next 15 years can attract 300M global subscribers and generate over $25 of earnings per share. The stock closed Friday up 18c to $115.21.
11/18/16
MACQ
11/18/16
NO CHANGE
MACQ
Netflix mentioned positively at M Science
UNH UnitedHealth
$152.11

-0.7 (-0.46%)

11/09/16
MZHO
11/09/16
DOWNGRADE
Target $135
MZHO
Neutral
UnitedHealth downgraded to Neutral on Republican win at Mizuho
As previously reported, Mizuho analyst Sheryl Skolnick downgraded UnitedHealth to Neutral from Buy citing Donald Trump's election and the move to a GOP Congress. Following the election results, Skolnick sees an "extreme risk" for the ACA to be repealed and replaced and for the loss of the Medicaid expansion, both of which she notes have been primary drivers of results for hospitals and health plans. She cut her price target on the stock to $135 from $169.
11/09/16
BERN
11/09/16
NO CHANGE
BERN
Health insurers to see multiple catalysts from Trump presidency, says Bernstein
Bernstein analyst Lance Wilkes says that "repealing and replacing Obamacare will be Trump's primary focus." The analyst expects health insurers to benefit from from the repeal of ACA taxes and the elimination of requirements to spend a certain percentage of revenue on medical costs. Wilkes expects Anthem (ANTM) and Blue Cross/Blue Shield providers to benefit from the elimination of public exchanges and broad coverage requirements. Other health insurers include Aetna (AET), Centene (CNC), Cigna (CI), Health Net (HNT), Humana (HUM), Molina Healthcare (MOH), UnitedHealth (UNH) and WellCare (WCG).
11/09/16
MZHO
11/09/16
DOWNGRADE
MZHO
Neutral
UnitedHealth downgraded to Neutral from Buy at Mizuho
10/19/16
LEER
10/19/16
NO CHANGE
Target $175
LEER
Outperform
UnitedHealth price target raised to $175 from $165 at Leerink
Leerink analyst Ana Gupte raised her price target for UnitedHealth to $175 from $165 after the company reported a "solid beat and raise" Q3, giving her more confidence in the strength of the company's diversified platform and execution while also offering positive read-across for Commercial Fully Insured & Individual fundamentals to the rest of the group. The analyst reiterates an Outperform rating on the shares.
SCVL Shoe Carnival
$30.27

-1.18 (-3.75%)

06/07/16
SIDC
06/07/16
INITIATION
Target $27
SIDC
Neutral
Shoe Carnival initiated with a Neutral at Sidoti
Target $27.
09/15/16
SUSQ
09/15/16
INITIATION
Target $27
SUSQ
Neutral
Shoe Carnival initiated with a Neutral at Susquehanna
Susquehanna analyst Sam Poser initiated Shoe Carnival with a Neutral and a $27 price target.
09/15/16
SUSQ
09/15/16
INITIATION
Target $27
SUSQ
Neutral
Shoe Carnival initiated with a Neutral at Susquehanna
Target $27.
03/30/16
STPT
03/30/16
DOWNGRADE
STPT
Hold
Shoe Carnival downgraded to Hold from Buy at Standpoint Research
NVLS Nivalis Therapeutics
$6.25

-0.03 (-0.48%)

09/13/16
RAJA
09/13/16
INITIATION
Target $20
RAJA
Outperform
Nivalis Therapeutics initiated with an Outperform at Raymond James
Raymond James analyst Christopher Raymond initiated Nivalis Therapeutics with an Outperform and a $20 price target. Raymond believes Nivalis' lead asset cavosonstat could provide one of the earliest triple-combo readouts in the cystic fibrosis space and views risk/reward as favorable ahead of the readout.
FOLD Amicus
$8.32

-0.58 (-6.52%)

08/22/16
GSCO
08/22/16
NO CHANGE
GSCO
Goldman lists companies to be in focus after Medivation deal
After Pfizer (PFE) announced it has agreed to acquire Medivation (MDVN) for $81.50 per share in cash, Goldman Sachs analyst Salveen Richter said he expects a focus on other commercial small-to-mid-cap cancer companies, including Incyte (INCY), Seattle Genetics (SGEN), ARIAD (ARIA) and Exelixis (EXEL). Also noting that Sanofi (SNY), which was pursuing Medivation, has recently suggested an interest in a rare disease transaction up to potentially as large as $20B, he would expect rare disease companies of that size - such as BioMarin (BMRN), Amicus (FOLD) and Ultragenyx (RARE) - to be in focus as well.
10/07/16
GSCO
10/07/16
NO CHANGE
GSCO
Smid-cap Biotech sector upgraded to Attractive from Neutral at Goldman
Goldman analyst Salveen Richter upgraded the Smid-cap biotechnology to Attractive and said he favors and companies with near-term pipeline data or regulatory events where he has conviction.Names he recommends are Buy rated BioMarin (BMRN), bluebird bio (BLUE), GW Pharma (GWPH), Incyte (INCY), Kite (KITE), and Sage (SAGE).
07/20/16
JPMS
07/20/16
NO CHANGE
Target $13
JPMS
Overweight
Amicus risk/reward 'compelling' at current levels, says JPMorgan
JPMorgan analyst Anupam Rama views the risk/reward for shares of Amicus Therapeutics at current levels as "compelling." After declining 39% year-to-date, Amicus is essentially only pricing in outside the U.S. Galafold sales in Fabry disease plus cash, Rama tells investors in a research note. Very little credit is being given to the company's U.S. migalastat, Zorblisa or the Pompe program, which all have events in the second half of 2016, the analyst contends. Rama thinks only one of the three need to hit for the stock to trade "materially higher," with upside ranging from 20%-100%-plus on a single success, and "meaningfully more upside" potential on multiple positive updates. Rama reiterates an Overweight rating on Amicus with a $13 price target.
06/14/16
LEER
06/14/16
NO CHANGE
Target $19
LEER
Outperform
Protalix development encouraging for Amicus Galafold, says Leerink
Leerink analyst Joseph Schwartz is "incrementally encouraged" by the news that Protalix (PLX) reached an agreement with the FDA to advance its Fabry ERT into a pivotal trial, just before Amicus' (FOLD) meeting with the agency to discuss a regulatory path for its Galafold. Amicus was poised to emphasize non-renal data in the upcoming FDA meeting, but now the company has "another way to win" by using renal data, the analyst tells investors in a research note. Schwartz now assigns a 33% probability for Galafold. The analyst reiterates an Outperform rating on Amicus' stock and raised his price target on the shares to $19 from $17.
COTV Cotiviti Holdings
$31.45

-0.43 (-1.35%)

10/28/16
10/28/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. L-3 Communications (LLL) initiated with an Outperform at Baird and a Hold at Vertical Research. 2. Twilio (TWLO) initiated with a Neutral at MUFG. 3. Cotiviti Holdings (COTV) assumed with an Overweight at JPMorgan. 4. Raytheon (RTN) and General Dynamics (GD) were initiated with a Buy at Vertical Research while the firm initiated Boeing (BA) and Northrop Grumman (NOC) with a Hold. 5. Allscripts (MDRX) assumed with an Overweight at JPMorgan. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
11/11/16
RHCO
11/11/16
NO CHANGE
RHCO
Cotiviti Holdings outlook positive, says SunTrust
After Cotiviti fell following its results, SunTrust analyst Sandy Draper blames the decline on worries related to the possible repeal of the ACA. Draper says that the company's beat and raise results indicate that its core business is performing well, and he thinks that stock's outlook is positive heading into 2017. He keeps a Buy rating on the shares.
10/28/16
JPMS
10/28/16
INITIATION
Target $39
JPMS
Overweight
Cotiviti Holdings assumed with an Overweight at JPMorgan
JPMorgan analyst Stephanie Davis assumed coverage of Cotiviti Holdings with an Overweight rating and $39 price target after taking over lead coverage from Lisa Gill.
10/10/16
FANA
10/10/16
INITIATION
Target $42
FANA
Overweight
Cotiviti Holdings initiated with an Overweight at First Analysis
First Analysis analyst Frank Sparacino initiated Cotiviti with an Overweight rating and a price target of $42.
BOJA Bojangles
$19.70

-0.35 (-1.75%)

09/20/16
09/20/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Ford (F) initiated with a Buy at Nomura. 2. Intel (INTC) was initiated with a Positive at Susquehanna while the firm initiated AMD (AMD) with a Neutral. 3. HSN, Inc. (HSNI) initiated with an Underperform at BofA/Merrill. 4. Bojangles (BOJA) initiated with a Strong Buy at CL King. 5. D.R. Horton (DHI) initiated with an Outperform at Wedbush. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
03/11/16
SPHN
03/11/16
UPGRADE
SPHN
Overweight
Bojangles upgraded to Overweight from Equal Weight at Stephens
09/19/16
KING
09/19/16
INITIATION
Target $21
KING
Strong Buy
Bojangles initiated with a Strong Buy at CL King
CL King analyst Michael W. Gallo initiated Bojangles with a Strong Buy and a $21 price target. The analyst believes Bojangles is a compelling growth story within the QSR space and has room for significant unit expansion and earnings growth over time.
11/25/16
PIPR
11/25/16
NO CHANGE
PIPR
Piper thinks blocking of Overtime Rule came too late
An Obama-appointed judge in Texas surprisingly blocked the Overtime Rule set to take effect on December 1, Piper Jaffray analysts in the Hardlines Retail & Specialty Products space tell investors in a research note. The analysts say that regardless of whether the injunction is upheld, their research suggests that the ruling comes too late for larger companies to pull back on the planned Overtime Rule change. Payroll and IT systems are likely set to adjust this coming Sunday, they point out. Piper's analysts expect the expense headwinds from the OT rule change for retailers/restaurants to remain in place. The retailers they believe that are most impacted from the rule are Dollar General (DG), Dollar Tree (DLTR), Regis (RGS) and Sally Beauty (SBH). The restaurants they believe are most impacted are Bojangles (BOJA), Starbucks (SBUX), Sonic (SONC), Noodles & Company (NDLS), Potbelly (PBPB), Del Taco (TACO) and Zoe's Kitchen (ZOES).
TCBI Texas Capital
$73.15

-2.35 (-3.11%)

10/06/16
WEDB
10/06/16
INITIATION
Target $54
WEDB
Neutral
Texas Capital initiated with a Neutral at Wedbush
Wedbush analyst Peter Winter initiated Texas Capital with a Neutral and a $54 price target.
11/03/16
RAJA
11/03/16
UPGRADE
RAJA
Strong Buy
Texas Capital upgraded to Strong Buy from Outperform at Raymond James
11/11/16
DBAB
11/11/16
DOWNGRADE
Target $66
DBAB
Hold
Texas Capital downgraded to Hold from Buy at Deutsche Bank
Deutsche Bank analyst Dave Rochester downgraded Texas Capital Bancshares to Hold citing valuation following the recent rally. The analyst keeps a $66 price target for the shares.
11/18/16
COMP
11/18/16
DOWNGRADE
Target $67
COMP
Neutral
Texas Capital downgraded to Neutral from Buy at Compass Point
Compass Point analyst Scott Valentin downgraded Texas Capital to Hold and raised its price target to $67 from $64 on valuation and said Trumps victory has pushed bank stocks to new near-term highs.
SITE SiteOne Landscape
$35.07

-0.53 (-1.49%)

11/15/16
RHCO
11/15/16
NO CHANGE
RHCO
SiteOne weakness creates 'excellent' entry point, says SunTrust
SunTrust analyst Keith Hughes blames the recent weakness in SiteOne's stock on multiple compression in its sector, along with poor weather and weak construction trends that hurt the company's Q3 results. The analyst says that the company should benefit from strong acquisitions and margin expansion going forward, making its current valuation an "excellent" entry point. He keeps a Buy rating on the shares.
08/18/16
UBSW
08/18/16
DOWNGRADE
UBSW
Neutral
SiteOne Landscape downgraded to Neutral from Buy at UBS
08/18/16
RHCO
08/18/16
NO CHANGE
RHCO
SiteOne Landscape should be bought on weakness, says SunTrust
SunTrust analyst Keith Hughes says that SiteOne's Q2 miss was caused by "a forecasting error." However, he believes that the company generated "outstanding" margin growth and he expects that trend to continue for some time. Hughes remains upbeat on the company's long-term outlook and keeps a Buy rating.
06/23/16
RBCM
06/23/16
NO CHANGE
RBCM
SiteOne Landscape price target raised to $37 from $32 at RBC Capital
RBC Capital increased its price target on SiteOne after the company reported stronger than expected results. The firm says that the company is benefiting from "solid demand" and "strong execution." It keeps an Outperform rating on the shares.
CHKE Cherokee
$10.00

-0.5 (-4.76%)

12/17/15
BMUR
12/17/15
NO CHANGE
Target $23
BMUR
Buy
Cherokee price target lowered to $23 from $28 at Brean Capital
Brean Capital lowered its price target on Cherokee to $23 from $28 following Q3 results that came in below expectations. The firm believes the company's growth was affected by initiatives that will eventually leverage its 360 degree platform, but they see product launches and increasing brand awareness and multiple growth opportunities keeping the company well positioned to increase earnings. Brean Capital reiterated its Buy rating on Cherokee shares.
06/13/16
ROTH
06/13/16
NO CHANGE
Target $18
ROTH
Buy
Cherokee price target lowered to $18 from $22 at Roth Capital
Roth Capital analyst Dave King lowered his price target for Cherokee to $18 from $22 after the company reported quarterly results. While EPS fell short of estimates on higher expenses, Cherokee's revenue exceeded consensus, helped by organic growth for the company's namesake brand, the analyst tells investors in a research note. King continues to recommend Cherokee for its unique brand licensing approach, robust margins, and strong cash flows. He reiterates a Buy rating on the shares.
ALL Allstate
$72.04

-0.01 (-0.01%)

06/02/16
SBSH
06/02/16
DOWNGRADE
Target $31
SBSH
Sell
Progressive downgraded to Sell from Neutral at Citi
Citi analyst James Naklicki downgraded Progressive (PGR) to Sell saying consensus margin and earnings expectations are too optimistic. The company's margins should "deteriorate materially" as it books new business at a combined ratio of around 129%. The analyst cut his 2016 earnings per share estimate to $1.65, which he notes is well below consensus, and dropped his price target for the shares to $31 from $36. Naklicki recommends a pair trade of long Allstate (ALL), short Progressive.
05/20/16
JANY
05/20/16
NO CHANGE
JANY
Buy
Allstate estimates lowered on catastrophe losses at Janney Capital
After Allstate announced April pre-tax catastrophe losses of $633M, which was above Janney Capital's estimate, analyst Robert Glasspiegel lowered his Q2 EPS estimate to 42c from 73c and his FY16 EPS estimate to $3.93 from $4.25. However, he maintains his 2017 EPS estimate of $6.00 and keeps a Buy rating on Allstate shares.
05/09/16
DBAB
05/09/16
NO CHANGE
Target $79
DBAB
Buy
Allstate price target raised to $79 from $71 at Deutsche Bank
Deutsche Bank analyst Joshua Shanker raised his price target for Allstate to $79 saying the company's margin improvements "have only just begun." The analyst expects Allstate will continue to seek rate increases through 2016 and sees "meaningful" share upside from current levels. Shanker keeps a Buy rating on Allstate.
02/05/16
02/05/16
UPGRADE

On The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Abbott (ABT) upgraded on valuation at Argus... Allstate (ALL) upgraded to Buy from Neutral at Citi... CACI (CACI) upgraded to Buy from Neutral at Citi... Coca-Cola Enterprises (CCE) upgraded to Neutral from Negative at Susquehanna... Coca-Cola (KO) upgraded to Neutral from Negative at Susquehanna... Comcast (CMCSA) upgraded following Q4 results at Argus... DCT Industrial (DCT) upgraded to Neutral from Underperform at Credit Suisse... Fluidigm (FLDM) upgraded to Buy from Neutral at Mizuho... Glu Mobile (GLUU) upgraded to Buy from Hold at Benchmark... Goldman Sachs (GS) upgraded to Buy at UBS... JPMorgan (JPM) upgraded to Buy from Neutral at UBS... KeyCorp (KEY) upgraded to Buy from Neutral at UBS... Kona Grill (KONA) upgraded to Outperform from Market Perform at Telsey Advisory... LPL Financial (LPLA) upgraded to Neutral at Susquehanna... Level 3 (LVLT) upgraded to Overweight from Equal Weight at Stephens... Resolute Forest (RFP) upgraded to Outperform from Sector Perform at RBC Capital... Suburban Propane (SPH) upgraded to Buy from Neutral at Citi... Sysco (SYY) upgraded at Argus... U.S. Concrete (USCR) upgraded to Buy from Neutral at Citi... Ubiquiti (UBNT) upgraded to Buy from Hold at Wunderlich... United Natural Foods (UNFI) upgraded to Sector Perform from Underperform at RBC Capital... Weatherford (WFT) upgraded to Strong Buy from Market Perform at Raymond James... Whole Foods (WFM) upgraded to Neutral from Underperform at Longbow... Wi-LAN (WILN) upgraded to Speculative Buy from Hold at Canaccord.

TODAY'S FREE FLY STORIES

BMRN

BioMarin

$82.21

-1.12 (-1.34%)

, ESALY

Eisai

$57.91

0.59 (1.03%)

04:55
12/04/16
12/04
04:55
12/04/16
04:55
Conference/Events
American Epilepsy Society to hold annual meeting »

70th Annual Meeting of…

BMRN

BioMarin

$82.21

-1.12 (-1.34%)

ESALY

Eisai

$57.91

0.59 (1.03%)

GWPH

GW Pharmaceuticals

$112.32

3.04 (2.78%)

IART

Integra LifeSciences

$75.78

-1.07 (-1.39%)

MDT

Medtronic

$72.01

0.13 (0.18%)

MNK

Mallinckrodt

$53.61

0.51 (0.96%)

NVTA

Invitae

$6.95

0.16 (2.36%)

SAGE

SAGE Therapeutics

$49.02

-0.23 (-0.47%)

WTKWY

Wolters Kluwer

$34.08

-0.39 (-1.13%)

ZGNX

Zogenix

$13.05

0.35 (2.76%)

ZYNE

Zynerba

$13.64

0.83 (6.48%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 06

    Dec

  • 07

    Dec

  • 12

    Dec

  • 14

    Dec

  • 28

    Jan

  • 27

    Apr

CELG

Celgene

$117.63

-1.24 (-1.04%)

04:55
12/04/16
12/04
04:55
12/04/16
04:55
Conference/Events
Celgene to hold an analyst and investor event »

Management holds an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

  • 06

    Dec

INCY

Incyte

$102.02

2.09 (2.09%)

, PFE

Pfizer

$31.63

0.17 (0.54%)

04:55
12/04/16
12/04
04:55
12/04/16
04:55
Conference/Events
Canaccord biotech analyst to hold a dinner meeting »

In conjunction with the…

INCY

Incyte

$102.02

2.09 (2.09%)

PFE

Pfizer

$31.63

0.17 (0.54%)

LLY

Eli Lilly

$67.71

1.74 (2.64%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

  • 06

    Dec

  • 15

    Dec

JUNO

Juno Therapeutics

$20.43

0.53 (2.66%)

, KITE

Kite Pharma

$50.76

0.04 (0.08%)

21:25
12/03/16
12/03
21:25
12/03/16
21:25
Conference/Events
Canaccord biotech analyst to hold a dinner meeting »

In conjunction with the…

JUNO

Juno Therapeutics

$20.43

0.53 (2.66%)

KITE

Kite Pharma

$50.76

0.04 (0.08%)

BLUE

bluebird bio

$69.75

1.1 (1.60%)

NVS

Novartis

$68.17

0.42 (0.62%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Dec

  • 03

    Dec

  • 06

    Dec

09:15
12/03/16
12/03
09:15
12/03/16
09:15
General news
Breaking General news story  »

New York Federal Reserve…

09:15
12/03/16
12/03
09:15
12/03/16
09:15
General news
Breaking General news story  »

New York Federal Reserve…

04:55
12/03/16
12/03
04:55
12/03/16
04:55
General news
Breaking General news story  »

New York Federal Reserve…

04:55
12/03/16
12/03
04:55
12/03/16
04:55
General news
Breaking General news story  »

New York Federal Reserve…

BMRN

BioMarin

$82.21

-1.12 (-1.34%)

, ESALY

Eisai

$57.91

0.59 (1.03%)

04:55
12/03/16
12/03
04:55
12/03/16
04:55
Conference/Events
American Epilepsy Society to hold annual meeting »

70th Annual Meeting of…

BMRN

BioMarin

$82.21

-1.12 (-1.34%)

ESALY

Eisai

$57.91

0.59 (1.03%)

GWPH

GW Pharmaceuticals

$112.32

3.04 (2.78%)

IART

Integra LifeSciences

$75.78

-1.07 (-1.39%)

MDT

Medtronic

$72.01

0.13 (0.18%)

MNK

Mallinckrodt

$53.61

0.51 (0.96%)

NVTA

Invitae

$6.95

0.16 (2.36%)

SAGE

SAGE Therapeutics

$49.02

-0.23 (-0.47%)

WTKWY

Wolters Kluwer

$34.08

-0.39 (-1.13%)

ZGNX

Zogenix

$13.05

0.35 (2.76%)

ZYNE

Zynerba

$13.64

0.83 (6.48%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Dec

  • 05

    Dec

  • 06

    Dec

  • 07

    Dec

  • 12

    Dec

  • 14

    Dec

  • 28

    Jan

  • 27

    Apr

WMT

Wal-Mart

$70.88

0.21 (0.30%)

18:17
12/02/16
12/02
18:17
12/02/16
18:17
Periodicals
Wal-Mart to pay $7.5M to settle same-sex spouse benefit case, Reuters reports »

Wal-Mart said it would…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GMED

Globus Medical

$21.89

0.12 (0.55%)

, TLN

Talen Energy

18:14
12/02/16
12/02
18:14
12/02/16
18:14
Hot Stocks
S&P announces changes to S&P MidCap 400, S&P SmallCap 600 indices »

S&P Dow Jones Indices…

GMED

Globus Medical

$21.89

0.12 (0.55%)

TLN

Talen Energy

UMBF

UMB Financial

$77.00

-0.43 (-0.56%)

IM

Ingram Micro

$38.88

1.31 (3.49%)

HMST

HomeStreet

$29.35

-0.2 (-0.68%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JNJ

Johnson & Johnson

$111.96

0.58 (0.52%)

, ALIOF

Actelion

$206.01

15.21 (7.97%)

18:11
12/02/16
12/02
18:11
12/02/16
18:11
Periodicals
Johnson & Johnson said to raise offer for Actelion above $250, Bloomberg says »

Johnson &…

JNJ

Johnson & Johnson

$111.96

0.58 (0.52%)

ALIOF

Actelion

$206.01

15.21 (7.97%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CE

Celanese

$79.10

0.3 (0.38%)

18:00
12/02/16
12/02
18:00
12/02/16
18:00
Hot Stocks
Celanese to raise list, off-list selling prices for paraformaldehyde »

Celanese Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HMST

HomeStreet

$29.35

-0.2 (-0.68%)

, GMED

Globus Medical

$21.89

0.12 (0.55%)

17:56
12/02/16
12/02
17:56
12/02/16
17:56
Hot Stocks
On The Fly: After Hours Movers »

HIGHER: HomeStreet…

HMST

HomeStreet

$29.35

-0.2 (-0.68%)

GMED

Globus Medical

$21.89

0.12 (0.55%)

BGS

B&G Foods

$42.50

0.2 (0.47%)

ZEN

Zendesk

$21.17

0.34 (1.63%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

  • 09

    Jan

ZEN

Zendesk

$21.17

0.34 (1.63%)

17:53
12/02/16
12/02
17:53
12/02/16
17:53
Hot Stocks
Zendesk says SVPs Amanda Kleha and Marcus Bragg to resign »

On November 29, Amanda…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

AIXG

Aixtron

$3.97

-0.05 (-1.24%)

17:42
12/02/16
12/02
17:42
12/02/16
17:42
Periodicals
President Obama blocks China's Fujian from acquiring Aixtron, CNBC reports »

President Barack Obama…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CX

CEMEX

$7.83

0.09 (1.16%)

17:31
12/02/16
12/02
17:31
12/02/16
17:31
Hot Stocks
CEMEX to divest ready-mix concrete pumping assets in Mexico »

CEMEX announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SRNE

Sorrento Therapeutics

$5.15

-0.1 (-1.90%)

17:30
12/02/16
12/02
17:30
12/02/16
17:30
Syndicate
Breaking Syndicate news story on Sorrento Therapeutics »

Sorrento files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

MBRX

Moleculin Biotech

$2.63

-0.14 (-5.05%)

17:29
12/02/16
12/02
17:29
12/02/16
17:29
Syndicate
Breaking Syndicate news story on Moleculin Biotech »

Moleculin Biotech files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

NEOG

Neogen

$61.59

-1.46 (-2.32%)

17:28
12/02/16
12/02
17:28
12/02/16
17:28
Hot Stocks
Neogen acquires U.K.-based Quat-Chem, terms undisclosed »

Neogen announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RRC

Range Resources

$36.36

-0.23 (-0.63%)

17:25
12/02/16
12/02
17:25
12/02/16
17:25
Hot Stocks
Breaking Hot Stocks news story on Range Resources »

SailingStone Capital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EOG

EOG Resources

$103.74

-1.01 (-0.96%)

17:25
12/02/16
12/02
17:25
12/02/16
17:25
Syndicate
Breaking Syndicate news story on EOG Resources »

EOG Resources files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

HMST

HomeStreet

$29.35

-0.2 (-0.68%)

, UMBF

UMB Financial

$77.00

-0.43 (-0.56%)

17:22
12/02/16
12/02
17:22
12/02/16
17:22
Hot Stocks
Breaking Hot Stocks news story on HomeStreet, UMB Financial »

HomeStreet to replace UMB…

HMST

HomeStreet

$29.35

-0.2 (-0.68%)

UMBF

UMB Financial

$77.00

-0.43 (-0.56%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UMBF

UMB Financial

$77.00

-0.43 (-0.56%)

, IM

Ingram Micro

$38.88

1.31 (3.49%)

17:21
12/02/16
12/02
17:21
12/02/16
17:21
Hot Stocks
UMB Financial to replace Ingram Micro in S&P 400 as of 12/6 close »

Tianjin Tianhai…

UMBF

UMB Financial

$77.00

-0.43 (-0.56%)

IM

Ingram Micro

$38.88

1.31 (3.49%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GMED

Globus Medical

$21.89

0.12 (0.55%)

, TLN

Talen Energy

17:20
12/02/16
12/02
17:20
12/02/16
17:20
Hot Stocks
Globus Medical to replace Talen Energy in S&P 400 as of 12/6 close »

Riverstone Holdings is…

GMED

Globus Medical

$21.89

0.12 (0.55%)

TLN

Talen Energy

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.